These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8343985)

  • 1. Rapid potentiometric determination of cholinesterases in plasma and red cells: application to eptastigmine monitoring.
    Cazzola E; Lattuada N; Zecca L; Radice D; Luzzana M; Imbimbo BP; Auteri A; Mosca A
    Chem Biol Interact; 1993 Jun; 87(1-3):265-8. PubMed ID: 8343985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.
    Auteri A; Mosca A; Lattuada N; Luzzana M; Zecca L; Radice D; Imbimbo BP
    Eur J Clin Pharmacol; 1993; 45(4):373-6. PubMed ID: 8299673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers.
    Imbimbo BP; Licini M; Schettino M; Mosca A; Onelli E; Zecca L; Giustina A
    J Clin Pharmacol; 1995 Mar; 35(3):285-90. PubMed ID: 7608318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study.
    Unni LK; Radcliffe J; Latham G; Sunderland T; Martinez R; Potter W; Becker RE
    Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):373-6. PubMed ID: 7934317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs.
    Cella SG; Imbimbo BP; Pieretti F; Müller EE
    Life Sci; 1993; 53(5):389-95. PubMed ID: 8336517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers.
    Mant T; Troetel WM; Imbimbo BP
    J Clin Pharmacol; 1998 Jul; 38(7):610-7. PubMed ID: 9702845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of food on the absorption of eptastigmine.
    Bjornsson TD; Troetel WM; Imbimbo BP
    Eur J Clin Pharmacol; 1998 May; 54(3):243-7. PubMed ID: 9681667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the decarbamoylation rates of physostigmine-inhibited plasma and red cell cholinesterases of man with other species.
    Wetherell JR; French MC
    Biochem Pharmacol; 1991 Jul; 42(3):515-20. PubMed ID: 1907148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
    Braida D; Sala M
    CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
    Sramek JJ; Block GA; Reines SA; Sawin SF; Barchowsky A; Cutler NR
    Life Sci; 1995; 56(5):319-26. PubMed ID: 7837931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of cholinesterase inhibition by eptastigmine in man.
    Unni LK; Hutt V; Imbimbo BP; Becker RE
    Eur J Clin Pharmacol; 1991; 41(1):83-4. PubMed ID: 1782985
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats.
    Scremin OU; Scremin AM; Heuser D; Hudgell R; Romero E; Imbimbo BP
    J Cereb Blood Flow Metab; 1993 Jul; 13(4):702-11. PubMed ID: 8314923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eptastigmine-phosphotriesterase combination in DFP intoxication.
    Tuovinen K; Kaliste-Korhonen E; Raushel FM; Hänninen O
    Toxicol Appl Pharmacol; 1996 Oct; 140(2):364-9. PubMed ID: 8887453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of mice against soman by pretreatment with eptastigmine and physostigmine.
    Tuovinen K; Hänninen O
    Toxicology; 1999 Dec; 139(3):233-41. PubMed ID: 10647923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection.
    Unni LK; Becker RE
    J Chromatogr; 1992 Jan; 573(2):275-81. PubMed ID: 1601960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mipafox differential inhibition assay for heart muscle cholinesterases: substrate specificity and inhibition of three isoenzymes by physostigmine and quinidine.
    Chemnitius JM; Haselmeyer KH; Gonska BD; Kreuzer H; Zech R
    Gen Pharmacol; 1997 Apr; 28(4):567-75. PubMed ID: 9147026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.
    Mosca A; Onelli E; Rosti E; Paleari R; Luzzana M; Imbimbo BP
    Ther Drug Monit; 1995 Jun; 17(3):230-8. PubMed ID: 7624918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection.
    Zecca L; Radice D; Mosca A; Pagella PG
    J Chromatogr; 1993 May; 615(1):169-73. PubMed ID: 8340457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
    Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
    Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.